ReviewThe oncologist2025
COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review.
Review in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Understanding the Psychological Impacts of Shielding From COVID-19 for Immunocompromised Individuals.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
From the beginning of the pandemic, people with cancer have experienced a high burden from COVID-19 compared with the general population, both in terms of severe COVID-19-related outcomes and reduced health-related quality of life and mental health. This review presents and discusses expert views on the burden of COVID-19 in individuals with cancer throughout the pandemic. The literature suggests that early in the pandemic, people with cancer had a disproportionately high risk of COVID-19-related hospitalization compared with the general population. This trend continued throughout the pandemic, even after the availability of vaccinations (including boosters) and the emergence of less virulent strains. Rates of hospitalization, intensive care unit admission, and mechanical ventilation varied across studies but were all seen to be higher in people with cancer and COVID-19 compared with the general population or those with cancer alone. Moreover, studies indicated worsened quality of life and mental health in these people during the pandemic and lockdown periods compared with prepandemic or postlockdown periods. Although COVID-19 has entered the endemic phase and is no longer a global health emergency, it remains a significant risk for people with cancer. Generally, COVID-19 continues to increase healthcare resource use, impair mental health, and reduce quality of life in this population, highlighting the need for continued real-world studies. Ongoing research is essential to evaluate the impact of COVID-19 on vaccinated people with cancer, particularly those undergoing systemic cancer therapy who may require continued guidance on preventive measures and treatments to mitigate the risk of severe COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.